The role of systemic and targeted therapies in brain metastases

Franceschi, Enrico; Bartolotti, Marco; Poggi, Rosalba; Battista, Monica Di; Palleschi, Dario; Brandes, Alba A

doi:10.1586/14737140.2014.856760

Cited by 7Brain Metastases and TreatmentGlioma Diagnosis and TreatmentManagement of metastatic bone disease

The role of systemic and targeted therapies in brain metastases

Franceschi, Enrico, Bartolotti, Marco, Poggi, Rosalba, Battista, Monica Di, Palleschi, Dario, Brandes, Alba A·2014·Expert Review of Anticancer Therapy

DOI 10.1586/14737140.2014.856760

Open this paper in CoChat — free account

Abstract

For many years, brain metastases (BMs) have been considered as the final stage of a disease course and engendered skepticism about the efficacy of treatments. Local treatments, mainly, whole-brain radiotherapy have been the standard of care, whereas chemotherapy has been considered of limited efficacy due to the potential role of blood-brain barrier.

Integrity signals

Registry

Crossref · 10.1586/14737140.2014.856760

Cites

88 of 88 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Retrospective studies and small phase II trials reported activity for EGFR TKIs in EGFR-mutated patients with brain metastases, with RR ranging from 60% to 100% and complete response rates that range 40%.
“Retrospective studies and small phase II trials reported intriguing activity for EGFR TKIs in EGFR-mutated patients with BMs, with RR ranging from 60% to 100% and complete response (CR) rates that ranges 40% [91, 92].”
From A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives (2015) · cites this paper as [92]

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · see citing works
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · see citing works
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261 · see citing works
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720 · see citing works
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302 · see citing works
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489 · see citing works
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419 · see citing works
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Wen, P. Y., Macdonald, D. R., Reardon, D. A., Cloughesy, T. F., Sorensen, A. G., Galanis, E., DeGroot, J. F., Wick, W., Gilbert, M. R., Lassman, A. B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3541 · Cited by 3,814 · see citing works
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I. J., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,542 · see citing works
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Geyer, C. E., Forster, J. K., Lindquist, D. L., Chan, S. Y. T., Romieu, C. G., Pieńkowski, T., Jagiełło-Gruszfeld, A., Crown, J. P., Chan, A., Kaufman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa064320 · Cited by 3,426 · see citing works
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381 · see citing works
A Randomized Trial of Surgery in the Treatment of Single Metastases to the Brain
Patchell, R. A., Tibbs, P. A., Walsh, J. W., Dempsey, R. J., Maruyama, Y., Kryscio, R. J., Markesbery, W. R., Macdonald, J. S., & Young, B. A. (1990) · New England Journal of Medicine · doi:10.1056/nejm199002223220802 · Cited by 3,138 · see citing works
Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trials
Gaspar, L. E., Scott, C., Rotman, M., Asbell, S. O., Phillips, T. L., Wasserman, T. H., McKenna, W. G., & Byhardt, R. W. (1997) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(96)00619-0 · Cited by 2,548 · see citing works
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Friedman, H. S., Prados, M. D., Wen, P. Y., Mikkelsen, T., Schiff, D., Abrey, L. E., Yung, W. K. A., Paleologos, N. A., Nicholas, M. K., Jensen, R. L., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8721 · Cited by 2,463 · see citing works
Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial
Andrews, D. W., Scott, C., Sperduto, P. W., Flanders, A. E., Gaspar, L. E., Schell, M. C., Werner‐Wasik, M., Demas, W. F., Ryu, J. K., Bahary, J.-P., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16250-8 · Cited by 2,418 · see citing works
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112302 · Cited by 2,156 · see citing works
Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases
Sperduto, P. W., Kased, N., Roberge, D., Xu, Z., Shanley, R., Luo, X., Sneed, P. K., Chao, S. T., Weil, R. J., Suh, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0527 · Cited by 1,425 · see citing works
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
Margolin, K., Ernstoff, M. S., Hamid, O., Lawrence, D., McDermott, D., Puzanov, I., Wolchok, J. D., Clark, J. I., Sznol, M., Logan, T. F., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70090-6 · Cited by 1,091 · see citing works
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
Falchook, G. S., Long, G. V., Kurzrock, R., Kim, K. B., Arkenau, H., Brown, M. P., Hamid, O., Infante, J. R., Millward, M., Pavlick, A. C., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60398-5 · Cited by 940 · see citing works
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
Long, G. V., Trefzer, U., Davies, M. A., Kefford, R. F., Ascierto, P. A., Chapman, P. B., Puzanov, I. J., Hauschild, A., Robert, C., Algazi, A. P., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70431-x · Cited by 919 · see citing works
Phase III Randomized Trial Comparing Three Platinum-Based Doublets in Advanced Non–Small-Cell Lung Cancer
Scagliotti, G. V., de Marinis, F., Rinaldi, M., Crinò, L., Gridelli, C., Ricci, S., Matano, E., Boni, C., Marangolo, M., Failla, G., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.02.068 · Cited by 889 · see citing works
Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer
Dijkers, E. C. F., Munnink, T. H. O., Kosterink, J. G. W., Brouwers, A. H., Jager, P. L., de Jong, J. R., van Dongen, G. A. M. S., Schroder, C. P., Hooge, M. N. L., & de Vries, E. G. E. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.12 · Cited by 810 · see citing works
Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study
Bachelot, T., Romieu, G., Campone, M., Dieras, V. C., Cropet, C., Dalenc, F., Jimenez, M., Rhun, É. L., Pierga, J., Gonçalvès, A., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70432-1 · Cited by 736 · see citing works
Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer
Lin, N., Dieras, V. C., Paul, D., Lossignol, D., Christodoulou, C., Stemmler, H., Roche, H. H., Liu, M., Greil, R., Ciruelos, E., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1080 · Cited by 660 · see citing works
Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood–brain barrier disruption
Kinoshita, M., McDannold, N. J., Jolesz, F. A., & Hynynen, K. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604318103 · Cited by 645 · see citing works
CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib
Costa, D. B., Kobayashi, S. S., Pandya, S. S., Yeo, W.-L., Shen, Z., Tan, W., & Wilner, K. D. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.1313 · Cited by 601 · see citing works
Stereotactic Radiosurgery for the Definitive, Noninvasive Treatment of Brain Metastases
Alexander, E., Moriarty, T. M., Davis, R., Wen, P. Y., Fine, H. A., Black, P. M., Kooy, H. M., & Loeffler, J. S. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.1.34 · Cited by 576 · see citing works
Phase II Trial of Lapatinib for Brain Metastases in Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
Lin, N., Carey, L., Liu, M., Younger, J., Come, S. E., Ewend, M. G., Harris, G. J., Bullitt, E., den Abbeele, A. D. V., Henson, J. W., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.3588 · Cited by 459 · see citing works
Breast Cancer Metastasis to the Central Nervous System
Weil, R. J., Palmieri, D., Bronder, J. L., Stark, A. M., & Steeg, P. S. (2005) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)61180-7 · Cited by 436 · see citing works
Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood–brain barrier
Stemmler, H., Schmitt, M., Willems, A., Bernhard, H., Harbeck, N., & Heinemann, V. (2006) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000236313.50833.ee · Cited by 411 · see citing works
Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer
Welsh, J. W., Komaki, R., Amini, A., Munsell, M. F., Unger, W., Allen, P. K., Chang, J. Y., Wefel, J. S., McGovern, S. L., Garland, L. L., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.1174 · Cited by 395 · see citing works
Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER
Brufsky, A., Mayer, M., Rugo, H. S., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2962 · Cited by 388 · see citing works
Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials
Viani, G. A., Afonso, S., Stefano, E. J., Fendi, L. I. D., & Soares, F. V. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-153 · Cited by 381 · see citing works
Gemcitabine and Cisplatin Versus Mitomycin, Ifosfamide, and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Randomized Phase III Study of the Italian Lung Cancer Project
Crinò, L., Scagliotti, G. V., Ricci, S., de Marinis, F., Rinaldi, M., Gridelli, C., Ceribelli, A., Bianco, R., Marangolo, M., Costanzo, F. D., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3522 · Cited by 362 · see citing works
Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial
Ceresoli, G. L., Cappuzzo, F., Gregorc, V., Bartolini, S., Crinò, L., & Villa, E. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh276 · Cited by 351 · see citing works
“Pulsatile” high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer
Grommes, C., Oxnard, G. R., Kris, M. G., Miller, V. A., Pao, W., Holodny, A. I., Clarke, J. L., & Lassman, A. B. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor121 · Cited by 349 · see citing works
Evaluation of Tumor Response, Disease Control, Progression-Free Survival, and Time to Progression As Potential Surrogate End Points in Metastatic Breast Cancer
Burzykowski, T., Buyse, M. E., Piccart, M. J., Sledge, G. W., Carmichael, J., Lück, H., Mackey, J. R., Nabholtz, J., Paridaens, R., Biganzoli, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.8407 · Cited by 348 · see citing works
Metastasis: a therapeutic target for cancer
Steeg, P. S., & Theodorescu, D. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1066 · Cited by 332 · see citing works
Brain metastases from lung cancer responding to erlotinib: the importance of<i>EGFR</i>mutation
Porta, R., Sánchez-Torres, J. M., Paz-Ares, L., Massutí, B., Reguart, N., Mayo, C., Lianes, P., Queralt, C., Guillem, V., Salinas, P., et al. (2011) · European Respiratory Journal · doi:10.1183/09031936.00195609 · Cited by 316 · see citing works
Safety of Bevacizumab in Patients With Non–Small-Cell Lung Cancer and Brain Metastases
Socinski, M. A., Langer, C. J., Huang, J. E., Kolb, M. M., Compton, P. G., Wang, L. E., & Akerley, W. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.0616 · Cited by 240 · see citing works
Bevacizumab Safety in Patients with Central Nervous System Metastases
Besse, B., Lasserre, S., Compton, P. G., Huang, J. Q., Augustus, S., & Rohr, U. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2439 · Cited by 238 · see citing works
Dabrafenib; Preclinical Characterization, Increased Efficacy when Combined with Trametinib, while BRAF/MEK Tool Combination Reduced Skin Lesions
King, A. J., Arnone, M. R., Bleam, M. R., Moss, K. G., Yang, J., Fedorowicz, K. E., Smitheman, K. N., Erhardt, J. A., Hughes‐Earle, A., Kane-Carson, L. S., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067583 · Cited by 222 · see citing works
Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis
Kim, J.-E., Lee, K. H., Choi, Y., Yoon, D. H., Kim, S.-W., Suh, C., & Lee, J. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2008.12.011 · Cited by 218 · see citing works
Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases
Capper, D., Berghoff, A. S., Magerle, M., İlhan, A., Wöehrer, A., Hackl, M., Pichler, J., Pusch, S., Meyer, J., Habel, A., et al. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0887-y · Cited by 212 · see citing works
CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01)
Pestalozzi, B. C., Holmes, E. M., de Azambuja, E., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70017-2 · Cited by 211 · see citing works
Lapatinib Distribution in HER2 Overexpressing Experimental Brain Metastases of Breast Cancer
Taskar, K. S., Rudraraju, V., Mittapalli, R. K., Samala, R., Thorsheim, H. R., Lockman, J. A., Gril, B., Hua, E., Palmieri, D., Polli, J. W., et al. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0601-8 · Cited by 202 · see citing works
Cancer metastasis as a therapeutic target
Sleeman, J. P., & Steeg, P. S. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.02.039 · Cited by 198 · see citing works
Cisplatin Plus Gemcitabine Versus a Cisplatin-Based Triplet Versus Nonplatinum Sequential Doublets in Advanced Non–Small-Cell Lung Cancer: A Spanish Lung Cancer Group Phase III Randomized Trial
Alberola, V., Camps, C., Provencio, M., Isla, D., Rosell, R., Vadell, C., Bover, I., Ruiz‐Casado, A., Azagra, P., Jiménez, U., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.038 · Cited by 193 · see citing works
Resection of brain metastases from non-small-cell lung carcinoma. Results of therapy. Memorial Sloan-Kettering Cancer Center Thoracic Surgical Staff.
BURT, M. E., Wroński, M., Arbit, E., et al. (1992) · PubMed · Cited by 189 · see citing works
Effect of gefitinib (‘Iressa’, ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer
Hotta, K., Kiura, K., Ueoka, H., Tabata, M., Fujiwara, K., Kozuki, T., Okada, T., Hisamoto, A., & Tanimoto, M. (2004) · Lung Cancer · doi:10.1016/j.lungcan.2004.04.036 · Cited by 176 · see citing works
Resection of brain metastases from non-small-cell lung carcinoma
BURT, M. E., Wroński, M., Arbit, E., et al. (1992) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/s0022-5223(19)34977-3 · Cited by 171 · see citing works
A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR)
Paz-Ares, L. G., Sanchez, J. M., Garcia-Velasco, A., Massutí, B., López-Vivanco, G., Provencio, M., Montés, A. F., Isla, D., Amador, M. L., & Rosell, R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.7020 · Cited by 164 · see citing works
Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine
Metro, G., Foglietta, J., Russillo, M., Stocchi, L., Vidiri, A., Giannarelli, D., Crinò, L., Papaldo, P., Mottolese, M., Cognetti, F., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq434 · Cited by 164 · see citing works
Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases
Lin, N., Eierman, W., Greil, R., Campone, M., Kaufman, B., Steplewski, K. M., Lane, S. R., Zembryki, D. L., Rubin, S. D., & Winer, E. P. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0629-y · Cited by 163 · see citing works
Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain
Wu, C., Li, Y. L., Wang, Z. M., Li, Z., Zhang, T. X., & Wei, Z. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2007.03.011 · Cited by 149 · see citing works
Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases – the UK experience
Sutherland, S., Ashley, S. E., Miles, D. W., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605586 · Cited by 146 · see citing works
Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity
Chiu, C., Tsai, C., Chen, Y., et al. (2004) · Lung Cancer · doi:10.1016/j.lungcan.2004.05.014 · Cited by 143 · see citing works
Gefitinib in Patients with Brain Metastases from Non–Small-Cell Lung Cancer: Review of 15 Clinical Cases
Namba, Y., Kijima, T., Yokota, S., et al. (2004) · Clinical Lung Cancer · doi:10.3816/clc.2004.n.026 · Cited by 138 · see citing works
Gefitinib as a First-Line Therapy of Advanced or Metastatic Adenocarcinoma of the Lung in Never-Smokers
Lee, K. H., Han, J., Lee, H. G., Lee, J. J., Lee, E. K., Kim, H. Y., Kim, H. K., Hong, E. K., & Lee, J. S. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2149 · Cited by 121 · see citing works
Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer
Braganca, K. C. D., Janjigian, Y. Y., Azzoli, C. G., Kris, M. G., Pietanza, M. C., Nolan, C. P., Omuro, A. M. P., Holodny, A. I., & Lassman, A. B. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0200-2 · Cited by 103 · see citing works
Primary chemotherapy for newly diagnosed nonsmall cell lung cancer patients with synchronous brain metastases compared with whole‐brain radiotherapy administered first
Lee, D. H., Han, J., Kim, H. T., Yoon, S. J., Pyo, H. R., Cho, K. H., Shin, S., Yoo, H., Lee, S. H., & Lee, J. S. (2008) · Cancer · doi:10.1002/cncr.23526 · Cited by 101 · see citing works
Results of Therapy
Baumel, H., & Deixonne, B. (1986) · Springer eBooks · doi:10.1007/978-3-642-71178-7_8 · Cited by 92 · see citing works
EGFR mutations in patients with brain metastases from lung cancer: Association with the efficacy of gefitinib
Shimato, S., Mitsudomi, T., Kosaka, T., et al. (2006) · Neuro-Oncology · doi:10.1215/15228517-2005-002 · Cited by 91 · see citing works
Response of Intracranial Metastases to Erlotinib Therapy
Fekrazad, M. H., Ravindranathan, M., & Jones, D. V. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.3751 · Cited by 77 · see citing works
Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases
Bartsch, R., Berghoff, A. S., Pluschnig, U., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.531 · Cited by 75 · see citing works
Stereotactic Radiosurgical Treatment of Cerebral Metastases Arising From Breast Cancer
Akyürek, S., Chang, E. L., Mahajan, A., et al. (2007) · American Journal of Clinical Oncology · doi:10.1097/01.coc.0000258365.50975.f6 · Cited by 68 · see citing works
Survival following whole brain radiation treatment for cerebral metastases: an audit of 474 patients
Broadbent, A. M., Hruby, G., Tin, M. M., et al. (2004) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2004.02.019 · Cited by 68 · see citing works
Up‐front chemotherapy and radiation treatment in newly diagnosed nonsmall cell lung cancer with brain metastases
Moscetti, L. I., Nelli, F., Felici, A., et al. (2006) · Cancer · doi:10.1002/cncr.22399 · Cited by 67 · see citing works
Bevacizumab and Paclitaxel for Breast Cancer Patients with Central Nervous System Metastases: A Case Series
Labidi‐Galy, S. I., Bachelot, T., Ray-Coquard, I. L., et al. (2009) · Clinical Breast Cancer · doi:10.3816/cbc.2009.n.021 · Cited by 66 · see citing works
An open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with brain metastases.
Dummer, R., Rinderknecht, J. D., Goldinger, S. M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.8548 · Cited by 62 · see citing works
Ineffectiveness of Crizotinib on Brain Metastases in Two Cases of Lung Adenocarcinoma with EML4-ALK Rearrangement
Maillet, D., Martel‐Lafay, I., Arpin, D., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318288dc2d · Cited by 56 · see citing works
Gamma knife surgery for the treatment of intracranial metastases from breast cancer
Goyal, S., Prasad, D., Harrell, F. E., et al. (2005) · Journal of neurosurgery · doi:10.3171/jns.2005.103.2.0218 · Cited by 53 · see citing works
Long-term Survival Following Surgical Treatment of Solitary Brain Metastasis in Non-small Cell Lung Cancer
Shahidi, H., & Kvale, P. A. (1996) · CHEST Journal · doi:10.1378/chest.109.1.271 · Cited by 53 · see citing works
Clinical outcomes in extracranial tumor sites and unusual toxicities with concurrent whole brain radiation (WBRT) and Erlotinib treatment in patients with non-small cell lung cancer (NSCLC) with brain metastasis
Olmez, I., Donahue, B. R., Butler, J. S., et al. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2010.01.018 · Cited by 49 · see citing works
Trial design on prophylaxis and treatment of brain metastases: Lessons learned from the EORTC Brain Metastases Strategic Meeting 2012
Preusser, M., Winkler, F., Collette, L., Haller, S., Marreaud, S. I., Soffietti, R., Klein, M., Reijneveld, J. C., Tonn, J., Baumert, B. G., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.07.002 · Cited by 42 · see citing works
EGF receptor tyrosine kinase inhibitors in the treatment of brain metastases from non-small-cell lung cancer
Bartolotti, M., Franceschi, E., & Brandes, A. A. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.121 · Cited by 36 · see citing works
Self-citation
Cerebel (EGF111438): An Open Label Randomized Phase III Study Comparing the Incidence of CNS Metastases in Patients (PTS) with HER2+ Metastatic Breast Cancer (MBC), Treated with Lapatinib Plus Capecitabine (LC) Versus Trastuzumab Plus Capecitabine (TC)
Pivot, X. B., Семиглазов, В. Ф., Żurawski, B. A., Allerton, R., Fabi, A., Ciruelos, E. M., Parikh, R., DeSilvio, M., Santillana, S., & Swaby, R. F. (2012) · Annals of Oncology · doi:10.1016/s0923-7534(20)34361-1 · Cited by 36 · see citing works
Bevacizumab in the treatment of five patients with breast cancer and brain metastases: Japan Breast Cancer Research Network-07 trial
Yamamoto, D., Iwase, S., Tsubota, et al. (2012) · OncoTargets and Therapy · doi:10.2147/ott.s36515 · Cited by 31 · see citing works
Long-lasting response to crizotinib in brain metastases due to EML4-ALK-rearranged non-small-cell lung cancer
Kinoshita, Y., Koga, Y., Sakamoto, A., & Hidaka, K. (2013) · BMJ Case Reports · doi:10.1136/bcr-2013-200867 · Cited by 31 · see citing works
Gefitinib as a First Line of Therapy in Non-Small Cell Lung Cancer with Brain Metastases
Ishida, A., Kanoh, K., Nishisaka, T., et al. (2004) · Internal Medicine · doi:10.2169/internalmedicine.43.718 · Cited by 31 · see citing works
Bevacizumab in the Treatment of a Patient with Metastatic Colorectal Carcinoma with Brain Metastases
Bhaskara, A., & Eng, C. (2008) · Clinical Colorectal Cancer · doi:10.3816/ccc.2008.n.010 · Cited by 28 · see citing works
Brain metastases of gastro-oesophageal cancer: evaluation of molecules with relevance for targeted therapies.
Preusser, M., Berghoff, A. S., Ilhan‐Mutlu, A., et al. (2013) · PubMed · Cited by 22 · see citing works
Bevacizumab as front-line treatment of brain metastases from solid tumors: a case series.
Zustovich, F., Ferro, A., Lombardi, G., et al. (2013) · PubMed · Cited by 21 · see citing works
Effect of gefitinib (ZD1839) on metastatic brain tumour
Takahashi, H., Ohrui, T., Ebihara, S., et al. (2003) · Lung Cancer · doi:10.1016/j.lungcan.2003.09.017 · Cited by 19 · see citing works
Treatment of brain metastases in uncommon tumors
Tosoni, A., Lumachi, F., & Brandes, A. A. (2004) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.4.5.783 · Cited by 15 · see citing works
Self-citation
Role of EGFR Inhibitors in the Treatment of Central Nervous System Metastases from Non-Small Cell Lung Cancer
Ceresoli, G. L. (2012) · Current Cancer Drug Targets · doi:10.2174/156800912799277430 · Cited by 15 · see citing works
A Patient With Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer With Development of Leptomeningeal Carcinomatosis While on Targeted Treatment With Crizotinib
Riess, J. W., Nagpal, S., Neal, J. W., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0054 · Cited by 13 · see citing works
Response rate to vemurafenib in BRAF-positive melanoma brain metastases.
Dzienis, M. R., & Atkinson, V. G. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.9081 · Cited by 5 · see citing works

Flagged first, then by citations

Sorted by citations

A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives
Russo, A., Franchina, T., Rita Ricciardi, G. R., Picone, A., Ferraro, G., Zanghì, M., Toscano, G., Giordano, A., & Adamo, V. (2015) · Oncotarget · doi:10.18632/oncotarget.4254 · Cited by 173 · see citing works

Authors: Franceschi, E., Bartolotti, M., Poggi, R., Battista, M. D., Palleschi, D., & Brandes, A. A.
Affiliations: Azienda USL di Bologna (IT)
Corresponding author: Brandes, Alba A
ORCID: Franceschi, Enrico
Brandes, Alba A
Venue: Expert Review of Anticancer Therapy
Publisher: Informa UK Limited
Published: 2013-11-26
Volume: 14
Issue: 1
Pages: 93-103
ISSN: 1473-7140 (ISSN-L)
1744-8328
DOI: 10.1586/14737140.2014.856760
OpenAlex: W2029745956
Cited by: 7
References: 88
Citations by year: 2025: 1 · 2021: 2 · 2017: 1 · 2016: 1 · 2015: 2
FWCI: 0.16
Type: journal article
Language: en
Open access: closed
Locations: Expert Review of Anticancer Therapy (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Brain Metastases and Treatment
Health Sciences › Medicine › Genetics › Glioma Diagnosis and Treatment
Health Sciences › Medicine › Surgery › Management of metastatic bone disease
Keywords: brain metastases, systemic therapy, targeted therapy, whole brain radiotherapy, chemotherapy, blood-brain barrier, treatment efficacy
MeSH terms: Antineoplastic Agents, Blood-Brain Barrier, Brain Neoplasms, Humans, Drug Design, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The role of systemic and targeted therapies in brain metastases

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks